Since 1981, a centralized histology laboratory has provided histologic services to investigators at MDACC.
The aim of the Research Histopathology Facility (RHF) is to provide technical support and consultation, develop and apply appropriate new techniques to support evolving research needs, and maintain the consistency and high quality needed to perform these tissue-based techniques. The RHF processes fixed and frozen specimens including cell line and mouse embryo preparations for histologic analysis in routine, thin and thick sections for immunohistochemistry and in situ hybridization;special staining;tissue transfer; DNAse- and RNAse-free procedures;frozen sections;sectioning of tissue microarray blocks;scalpel microdissection;and immunohistochemical staining. The RHF is available to all faculty members at MDACC, with preference given to investigators with peer-reviewed grants. The RHF occupies 740 sq ft of recently renovated laboratory space in the Department of Pathology on the North Campus and 370 sq ft in the R.E. """"""""Bob"""""""" Smith Research Building on the South Campus. Among the services provided are rapid preparation of high-quality standard histologic sections;application of special technologies as needed for selected projects, including preparation of frozen sections and tissue sections for histochemical, immunohistochemical, and in situ hybridization analysis;consultation with investigators to tailor technologies and methodologies to their special needs;and referral for consultation by organ-site subspecialty pathologists on interpretation of histopathology. Laser capture microdissection services will be added in the Fall of 2007. The RHF utilizes state-of-the-art equipment to complete its work, as during the past 2 years both laboratories have replaced their equipment to better serve their users. The RHF currently maintains a staff that includes a Shared Resource Director, a Co-Director, a Manager/Chief Technologist, 2 Senior Histology Technicians, 2 Research Histology Technicians, and 2 Histology Laboratory Assistants. During the past 5 years, the RHF was used by 287 investigators representing 18 different CCSG Programs, and use increased by 569%. Users with peer-reviewed funding accounted for 78% of service utilization and represented 53% of users. Future plans include continued improvement of the Histology Chargeback Database System, continuation of the equipment replacement cycle, expansion of the South Campus facility, and activation of laser capture microdissection services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-35
Application #
8144419
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
35
Fiscal Year
2010
Total Cost
$419,985
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications